Visual improvement in established central retinal vein occlusion with long-standing macular edema following systemic eculizumab treatment

Canadian Journal of Ophthalmology

Volumn 45, Issue 6, 2010, Pages 649-

  Lockington, David ^a   Imrie, Fraser ^a   Gillen, Jennifer ^b   Fitzpatrick, Amanda ^c   Willison, Hugh ^c  

^a GARTNAVEL GENERAL HOSPITAL   (United Kingdom)

^b Stirling Royal Infirmary   (United Kingdom)

^c UNIVERSITY OF GLASGOW   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

COMPLEMENT COMPONENT C5A RECEPTOR; ECULIZUMAB; VASCULOTROPIN; VISUAL PIGMENT;

AGED; CASE REPORT; HEMIRETINAL VEIN OCCLUSION; HUMAN; LETTER; MALE; MOTOR NEUROPATHY; OPHTHALMOLOGY; OPTIC DISK; OPTICAL COHERENCE TOMOGRAPHY; PAROXYSMAL NOCTURNAL HEMOGLOBINURIA; RETINA MACULA AGE RELATED DEGENERATION; RETINA MACULA EDEMA; VISUAL ACUITY;

EID: 78650452931     PISSN: 00084182     EISSN: 17153360     Source Type: Journal    
DOI: 10.3129/i10-060     Document Type: Letter

References (5)

1. Parker C. Eculizumab for paroxysmal nocturnal haemoglobinuria. Lancet 2009;373:759-67.
2. Rohrer B, Long Q, Coughlin B, et al. A targeted inhibitor of the alternative complement pathway reduces angiogenesis in a mouse model of age-related macular degeneration. Invest Ophthalmol Vis Sci 2009;50:3056-64.
3. Spaide RF, Chang LK, Klancnik JM, et al. Prospective study of intravitreal ranibizumab as a treatment for decreased visual acuity secondary to central retinal vein occlusion. Am J Ophthalmol 2009;147:298-306.
4. RodriguesEB, FarahME, Maia M, et al.Therapeutic monoclonal antibodies in ophthalmology. Prog Retin Eye Res 2009;28:117-44.
5. Cortright DN, Meade R, Waters SM, Chenard BL, Krause JE. C5a, but not C3a, increasesVEGF secretion in ARPE-19 human retinal pigment epithelial cells. Curr Eye Res 2009;34:57-61.